Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits.
Gruber
Scott A
SA
Doshi
Mona D
MD
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum; D044383:Black People; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006435:Renal Dialysis; D012086:Reoperation / Q000706:statistics & numerical data; D018570:Risk Assessment; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D001741:Black or African American
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; C512542:thymoglobulin; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus; D008775:Methylprednisolone